Sandoz Group AG

Sandoz Group AG is a Swiss multinational pharmaceutical company specializing in generic pharmaceuticals and biosimilars. Founded in 1886 in Basel, it has evolved into the global leader in providing affordable, high-quality versions of off-patent medicines, serving nearly 500 million patients across more than 100 countries. The company operates through key segments including retail generics with finished dosage forms of small-molecule drugs, biopharmaceuticals featuring biosimilars for conditions like cancer, diabetes, and arthritis, and anti-infectives producing active pharmaceutical ingredients and intermediates. Additionally, its B2B unit supplies APIs, finished dosage forms, and contract manufacturing services to third-party companies. Spun off from Novartis in October 2023 and headquartered in Basel, Switzerland, Sandoz Group AG employs over 22,000 people worldwide, with major operations in Europe, North America, and internationally. Its portfolio exceeds 1,500 products, emphasizing accessibility to essential therapies in healthcare and pharmaceuticals sectors.